These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 20303538)

  • 41. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
    Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
    J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
    Lerner SE; Blute ML; Bergstralh EJ; Bostwick DG; Eickholt JT; Zincke H
    J Urol; 1996 Jul; 156(1):137-43. PubMed ID: 8648775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
    May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
    J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
    Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Androgen regulation of ETS gene fusion transcripts in prostate cancer.
    Gasi D; Trapman J
    Methods Mol Biol; 2011; 776():335-48. PubMed ID: 21796535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 50. [Prostate cancer: the revolution of the fusion genes].
    Fernández-Serra A; Rubio-Briones J; García-Casado Z; Solsona E; López-Guerrero JA
    Actas Urol Esp; 2011; 35(7):420-8. PubMed ID: 21601955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
    Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
    BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.
    Casanova-Salas I; Rubio-Briones J; Calatrava A; Mancarella C; Masiá E; Casanova J; Fernández-Serra A; Rubio L; Ramírez-Backhaus M; Armiñán A; Domínguez-Escrig J; Martínez F; García-Casado Z; Scotlandi K; Vicent MJ; López-Guerrero JA
    J Urol; 2014 Jul; 192(1):252-9. PubMed ID: 24518785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy.
    Talantov D; Jatkoe TA; Böhm M; Zhang Y; Ferguson AM; Stricker PD; Kattan MW; Sutherland RL; Kench JG; Wang Y; Henshall SM
    J Urol; 2010 Oct; 184(4):1521-8. PubMed ID: 20723930
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.
    Darnel AD; Lafargue CJ; Vollmer RT; Corcos J; Bismar TA
    Cancer Biol Ther; 2009 Jan; 8(2):125-30. PubMed ID: 19029822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Fusion genes and prostate cancer. From discovery to prognosis and therapeutic perspectives].
    Beuzeboc P; Soulié M; Richaud P; Salomon L; Staerman F; Peyromaure M; Mongiat-Artus P; Cornud F; Paparel P; Davin JL; Molinié V
    Prog Urol; 2009 Dec; 19(11):819-24. PubMed ID: 19945666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
    Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC; Anand A; Sung CC; Heller G; Leversha MA; Cao L; Lilja H; Molina A; Sawyers CL; Fleisher M; Scher HI
    Eur Urol; 2011 Nov; 60(5):897-904. PubMed ID: 21802835
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion.
    Salagierski M; Schalken JA
    J Urol; 2012 Mar; 187(3):795-801. PubMed ID: 22245323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.